Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes

Pharmacy World and Science

Volumn 19, Issue 4, 1997, Pages 191-196

  Zoer, J ^a,b   Schrander van Der Meer, A M ^c   Van Dorp, W T ^c  

^a Central Pharmacy   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c Kennemer Gasthuis ^*  (Netherlands)

Author keywords

Dosage; Haemodialysis; Renal insufficiency; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; VANCOMYCIN;

EID: 0030863371     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008600104232     Document Type: Article

References (15)

1. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
2. Matzke GR, Zhanel GG, Guay DRP. Clinical Pharmacokinetics of vancomycin. Clin Pharmacokin 1986;11:257-82.
3. Bastani B, Spyker DA, Minocha A, Cummings R, Westervelt FB. In vivo comparison of three different hemodialysis membranes for vancomycin clearance: Cuprophan, cellulose acetate and polyacrylonitrile. Dial Transplant 1988;17:527-43.
4. Torras J, Cao C, Rivas MC, Cano M, Fernandez E, Montoliu J, et al. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991;36:35-41.
5. Lanese DM, Alfrey PS Molitoris BA. Markedly increased clearance of vancomycin during haemodialysis using polysulfon dialyzers. Kidney Int 1989;35:1409-12.
6. Cunha BA, Quintiliani R, Deglin JM , Irard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981;3:S269-S72.
7. Tan CC, Lee HS, Ti Ty, Lee EJC. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990;12:29-34.
8. De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 1989;4:635-9.
9. White LO, Edwards R, Holt HA, Lovering AM, Finch RG, Reeves DS. The in vitro degradation at 37°C in serum, CAPD fluid and phosphate buffered saline. J Antimicrob Chemother 1988;22:739-45.
10. Lee CC, Marbury TC. Drug therapy in patients undergoing haemodialysis. Clin Pharmacokin 1984;9:42-66.
11. Van Stone JC. Haemodialysis apparatus. In: Daugirdas JT and Ing TS, eds. Handbook of dialysis. Boston: Little Brown and Company 1988; chapter 3:21-39.
12. Hoenick NA, Kerr DNS. Dialysers. In: Drukker W, Parsons FM and Maher JF, eds. Replacement of renal function by dialysis. Boston: Martinus Nijhoff Publishers, 1986:122-3.
13. Hurst AH, Yoshinaga MA, Mitani GH, Foo KA, Jelliffe RW, Harrison EC. Application of a Bayesian method to monitor and adjust vancomycin regimens. Antimicrob Agents Chemother 1990;34:1165-71.
14. Böhler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ. Rebound of plasma vancomycin after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol 1992;42:635-40.
15. Newfield P, Roizen MF. Hazards of Rapid Administration of vancomycin. Ann Intern Med 1979;91:581.